Stocks · News reference

Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

Jul 27, 2026, 10:49 AMBenzinga Newsdesk

Jefferies analyst Akash Tewari initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Buy rating and announces Price Target of $50.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 10, 2026, 8:54 PMBenzinga Newsdesk
Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate
Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 85 percent increase over losses of $(2.60) per share from
Read original at benzinga
DMRA
BenzingaAug 5, 2026, 12:02 PMBenzinga Newsdesk
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Study Of DMR-001 To Treat Patients With Mutcalr-Driven Essential Thrombocythemia And Myelofibrosis
Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the initiation of the global Phase 1/1b CLARITY-101 clinical
Read original at benzinga
DMRA
BenzingaJul 30, 2026, 1:42 PMBenzinga Newsdesk
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40
Read original at benzinga
DMRA
BenzingaJul 27, 2026, 12:01 PMAvi Kapoor
This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.
Read original at benzinga
BSP BUD CIFR CORT DMRA